bioRxiv · 10.1101/2021.03.18.435908
Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration
Abstract
Site-specific integration of exogenous gene through genome editing is a promising strategy for gene therapy. However, homology-directed repair (HDR) only occurring in proliferating cells is inefficient especially in vivo. To investigate the efficacy of Cas9-induced homology-independent targeted integration (HITI) strategy for gene therapy, a rat hemophilia B model was generated and employed. Through HITI, a DNA sequence encoding the last exon of rat Albumin (rAlb) gene fused with a high-specific-activity Factor IX variant (R338L) using T2A, was inserted into the last intron of rAlb via recombinant adeno-associated viral (rAAV). The knock-in efficiency reached up to 3.66% determined by ddPCR. The clotting time was reduced to normal level 4 weeks after treatment, and the circulating FIX level was gradually increased up to 52% of normal during 9 months even after partial hepatectomy, demonstrating the amelioration of hemophilia. Through PEM-seq, no significant off-targeting effect was detected. Moreover, this study provides a promising therapeutic approach for hereditary diseases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Chen, X., Niu, X., Liu, Y., Zheng, R., Wang, L., Yang, L., Lu, J., Yin, S., Shao, Y., Wei, Y., Pan, J., Sayed, A., Ma, X., Liu, M., Jing, F., Hu, J., Zhang, X., Li, D.. 2021-03-19. Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration. https://doi.org/10.1101/2021.03.18.435908
Cite the original work for its findings. Save a collection to share your selection of sources.